A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab i
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refra
| Condition(s) | Advanced Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select t |
| Who can participate | Key Inclusion Criteria: * Phase 1 Dose Escalation: histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment. * Phase 2 Dose Expansion\*: select histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment. \*expansion cohort indications to be prioritized based on data from Phase 1 dose escalation. * Prior treatment with TROP2-directed therapy is permitted. * Measurable disease as defined by RECIST v1.1 or RANO-BM. * Willingness to provide archival tumor tissue when available or to undergo pre-treatment biopsy if not available. * Mandatory pre- and on-treatment biopsies for enrichment cohorts in Phase 1 dose escalation and Phase 2 expansion cohorts if deemed medically feasible and safe. * Eastern Coo |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | LigaChem Biosciences, Inc. |
| Locations | Los Angeles, California, United States; Boston, Massachusetts, United States; Ann Arbor, Michigan, United States; Nashville, Tennessee, United States; Dallas, Texas, United States; Dallas, Texas, United States (+2 more sites) |
| Start date | 2023-10-05 |
| NCT ID | NCT05941507 |
| Official listing | https://clinicaltrials.gov/study/NCT05941507 |